title: Human heart-type cytoplasmic fatty acid-binding protein in serum and urine during hyperacute myocardial infarction.
abstract: We have previously reported that serum and/or urinary human heart-type cytoplasmic fatty acid-binding protein (HH-FABPc) can be used as an early indicator of myocardial injury (Clin Biochem 1991; 24: 195-201). To confirm the usefulness of HH-FABPc as an early diagnostic indicator of acute myocardial infarction (AMI), its serum and urinary levels were measured in samples obtained within 6 h after the onset of acute coronary syndrome related symptoms. Samples were collected from 97 patients, who were composed of 63 with AMI, 24 with unstable angina and 10 with chest pain syndrome. The positivity of serum and urinary HH-FABPc and cardiac creatine kinase isozyme MB (CK-MB) was analyzed in these samples. Serum HH-FABPc levels in AMI were above normal in 91.4% (64/70) of the samples tested within 3 h of the onset of symptoms and in 100% (111/111) of those tested at 3-6 h. Elevated urinary HH-FABPc levels in AMI were obtained in 88.9% (8/9) of samples at 0-3 h and in 75% (6/8) at 3-6 h. CK-MB activity in AMI was positive in 20% (8/40) and 66.3% (53/80) of serum samples at 0-3 h and 3-6 h, respectively. HH-FABPc was always positive when a serum sample was positive for CK-MB. Serum HH-FABPc at 0-6 h in chest pain syndrome and in unstable angina were positive in 17.8% (5/28) and 56.7% (34/60), respectively. The elevated HH-FABPc in serum and urine was noted much earlier than that of CK-MB during the hyperacute phase of AMI. HH-FABPc showed high positive value in unstable angina, but it was low in normal coronary patients having chest pain. However, HH-FABPc level in unstable angina and chest pain syndrome was lower than that of AMI. Thus, HH-FABPc may be a valuable indicator for the diagnosis of hyperacute myocardial infarction.
authors.affiliation: Department of Internal Medicine, Osaka Medical College, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Tsuji
authors.forename: T
authors.initials: T
authors.lastname: Tanaka
authors.forename: K
authors.initials: K
authors.lastname: Sohmiya
authors.forename: Y
authors.initials: Y
authors.lastname: Hirota
authors.forename: K
authors.initials: K
authors.lastname: Yoshimoto
authors.forename: K
authors.initials: K
authors.lastname: Kinoshita
authors.forename: Y
authors.initials: Y
authors.lastname: Kusaka
authors.forename: K
authors.initials: K
authors.lastname: Kawamura
authors.forename: H
authors.initials: H
authors.lastname: Morita
authors.forename: S
authors.initials: S
authors.lastname: Abe
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000789:Angina, Unstable / Q000378:metabolism; D002352:Carrier Proteins / Q000378:metabolism*; D003402:Creatine Kinase / Q000097:blood; D003593:Cytoplasm / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism*; D005260:Female; D006801:Humans; D007527:Isoenzymes; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000652:urine*; D009206:Myocardium / Q000378:metabolism*; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity
chemical_list: D002352:Carrier Proteins; D005227:Fatty Acids; D007527:Isoenzymes; D003402:Creatine Kinase